Erythropoietin for the treatment of anemia in patients with hematologic disorders
This article introduces common data and our experience concerning the treatment with recombinant human erythropoietin anemia (r-HuEPO) in anemic patients with different disorders. We cited as an example some results of Eprex (Janssen-Cilag) therapy for patients with hematologic disorders in Russia....
Main Authors: | R. A. Podgurskaya, V. V. Pshibieva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2022-11-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/642 |
Similar Items
-
The Role of Erythropoietin in Preventing Anemia in the Premature Neonate
by: Oana Cristina Costescu, et al.
Published: (2023-11-01) -
Eprex in the management of anemia related to lymphoproliferative disorders
by: P. N. Barlamov, et al.
Published: (2022-11-01) -
Effectivity of Erythropoietin-Alpha between Fixed- and Adjusted-Dose in Chronic Kidney Disease Patients With Anemia on Hemodialysis
by: Mida Purwiningtyas, et al.
Published: (2021-01-01) -
APPLICATION OF ERYTHROPOIETIN THETA IN THERAPY OF ANEMIA IN ONCOLOGIC PATIENTS
by: O. A. GLADKOV, et al.
Published: (2016-12-01) -
Prolonged response to recombinant human erythropoietin treatment in patients with myelodysplastic syndrome at a single referral centre in Brazil
by: Anna Thawanny Gadelha Moura, et al.